Completed PHASE1 INTERVENTIONAL 1-arm NCT04146285

A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

A Phase I Clinical Trial of BAT4406F Injection on the Safety, Tolerability, and Pharmacokinetics in Patients With Neuromyelitis Optica Spectrum Disorders

Sponsor: Bio-Thera Solutions

Conditions Neuromyelitis Optica Spectrum Disorders

Interventions BAT4406F

Updated 8 times since 2019 Last updated: Jul 7, 2025 Started: Sep 1, 2020 Primary completion: Mar 13, 2023 Completion: Dec 25, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Neuromyelitis Optica Spectrum Disorders and is currently completed. Bio-Thera Solutions leads this study, which shows 8 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Aug 2025 — Present [monthly]

Completed PHASE1

Status: Unknown → Completed
May 2025 — Aug 2025 [monthly]

Unknown PHASE1

Status: Recruiting → Unknown
Sep 2024 — May 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
May 2023 — Jul 2024 [monthly]

Recruiting PHASE1

Status: Unknown Status → Recruiting

▶ Show 3 earlier versions

Jan 2022 — May 2023 [monthly]

Unknown Status PHASE1

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Jan 2022 [monthly]

Not Yet Recruiting PHASE1
Nov 2019 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bio-Thera Solutions

Data source: Bio-Thera Solutions

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China